Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MLLT4
REST API REST API
Homo sapiens
MLLT4 is differentially expressed in 300 experiments: 167 organism parts: bone marrow, brain, ... (165 more);, 208 disease states: normal, Huntington's disease, ... (206 more);, 102 cell types 436 cell lines 40 compound treatments and 80 other conditions.
Synonyms AF-6, AF6
Orthologs MLLT4 (Gallus gallus)   Mllt4 (Rattus norvegicus)   Mllt4 (Mus musculus)   MLLT4 (Bos taurus)   ENSCING00000014141 (Ciona intestinalis)   MLLT4 (1 of 2) (Danio rerio)   MLLT4 (2 of 2) (Danio rerio)   cno (Drosophila melanogaster)   mllt4 (Xenopus laevis)   Q6JDJ2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, adherens junction, adherens junction organization, protein binding, cell-cell adherens junction, cytoplasm, cell-cell junction, cell-cell junction organization, cell-cell signaling, cell adhesion molecule binding, cell junction, cell adhesion, nucleus, apical part of cell, protein C-terminus binding, signal transduction, cell junction assembly
InterPro Term PDZ/DHR/GLGF, Dilute, Dil_domain, FHA_dom, Ras-assoc
UniProt Accession A8MQ02, Q5TIH0, Q5TIH1, C9IYT9, P55196, Q5TIG5, C9JX92, Q5JPV5, Q96C95, E9PFY5, F8W9I4
Search EB-eye ENSG00000130396
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
HL-60
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
A549
2
E-GEOD-6013, E-GEOD-3202
MCF-10A
2
E-TABM-420, E-GEOD-14990
MOLT4
2
E-MTAB-37, E-MTAB-62
U251
2
E-GEOD-20089, E-MTAB-62
430 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (52 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
stromal cell
1
3
E-GEOD-1460, E-MEXP-2034, E-GEOD-10797, E-GEOD-3998
2
2
E-TABM-130, E-TABM-145
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-26672, E-GEOD-2248
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
endometrial tissue;vaginal tissue;myometrial tissue
1
E-MEXP-1251
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, ... (57 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-3726
control
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-20602
prostate carcinoma
2
E-MTAB-62, E-GEOD-7307
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
202 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-697, E-GEOD-5824, ... (28 experiments)

Factor Value U/D Experiments
hydroxyurea
2
E-GEOD-6431, E-GEOD-571
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
Cxcl12
1
1
E-GEOD-7307
vanadium pentoxide
1
E-GEOD-5339
U0126
1
E-GEOD-697
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
34 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
28 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-22513, E-MEXP-1251, E-GEOD-2191, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, ... (8 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-1751

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-868, E-GEOD-18005, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-10315, E-TABM-440, E-GEOD-20505, E-TABM-263, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (38 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-MEXP-1412, E-GEOD-1657

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-19330, E-GEOD-10896

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Processing time: 0.402 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM